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Abstract
Background—Fat transfer is an increasingly popular method for refining post-mastectomy 
breast reconstructions. However, concern persists that fat transfer may promote disease recurrence. 
Adipocytes are derived from adipose-derived stem cells and express adipocytokines that can 
facilitate active breast cancer cells in laboratory models. We sough to evaluate the association 
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between fat transfer to the reconstructed breast and cancer recurrence in patients diagnosed with 
local or regional invasive breast cancers.
Methods—A multi-center, case-cohort study was performed. Eligible patients from four centers 
(Memorial Sloan Kettering, MD Anderson, Alvin J. Siteman, and the University of Chicago) were 
identified by each site’s institutional tumor registry or cancer data warehouse. Eligibility criteria 
were: mastectomy with immediate breast reconstruction between 2006 and 2011, age above 21, 
female sex, and incident diagnosis of invasive ductal carcinoma, stage I, II or III. Cases consisted 
of all recurrences during the study period, and controls consisted of a 30% random sample of the 
study population. Cox proportional hazards regression was used to evaluate for association 
between fat transfer and time to recurrence in bivariate and multivariate models.
Results—The time to disease recurrence unadjusted hazard ratio for fat transfer was 0.99 (95% 
CI: 0.56, 1.7). After adjustment for age, body mass index, stage, HER2/Neu receptor status, and 
estrogen receptor status, the hazard ratio was was 0.97 (95% CI: 0.54, 1.8).
Conclusion—In this population of breast cancer patients who had mastectomy with immediate 
reconstruction, fat transfer was not associated with a higher risk of cancer recurrence.
INTRODUCTION
Fat transfer has gained widespread acceptance as a surgical technique for volume restoration 
and contour correction in breast reconstruction.(1) Members of the American Society of 
Plastic Surgeons (ASPS) report performing 25,456 fat transfer procedures in 2014,(2) and 
62% of surveyed members use this technique for breast reconstruction.(3) Despite its utility 
in improving aesthetic outcomes and optimization of symmetry following mastectomy with 
reconstruction, concerns regarding its oncologic safety persist.(4–9) These concerns are 
based on laboratory studies demonstrating that adipose derived stem cells (ASCs) and 
adipose derived growth factors can modulate the behavior of breast tumors in vitro and in 
animal models.(10–18) Also, laboratory studies have shown that ASCs modulate 
desmoplasia by elaborating extracellular matrix proteins, attenuate the antitumor immune 
response, and promote angiogenesis.(4, 5, 19, 20) A few retrospective clinical studies have 
suggested that fat transfer may increase the risk of locoregional recurrence after mastectomy 
for ductal carcinoma in situ (DCIS) or following partial mastectomy.(6–8, 21) Aside from a 
recent matched controlled study that shows fat transfer to be oncologically safe,(22) most 
clinical studies have been limited by inadequate power to detect small effects.
Recent guiding principles published by ASPS acknowledge that a limited body of evidence 
shows fat transfer following post-mastectomy breast reconstruction to be oncologically safe.
(23) These guiding principles, however, also acknowledge the need for additional high 
quality studies. As such, the ASPS clinical trials committee sought to establish whether 
adjunctive fat transfer is associated with a higher risk of recurrence in patients who have 
undergone mastectomy with reconstruction for invasive breast cancer. Our experimental 
design took into consideration the relatively low baseline rate of cancer recurrence, and the 
fact that while fat transfer is very popular currently, it gained prominence as a technique 
relatively recently. Moreover, we recognized the immediate need for information examining 
the impact of fat transfer on cancer recurrence given its popularity – something that a 
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prospective trial could not provide. The design of this study improves upon previous work 
with more representative selection of controls, adjustment for duration of follow-up, and 
sufficient power to detect a doubling of breast cancer recurrence risk.
METHODS
Study design
A case-cohort design was used. The case-cohort approach allows for greater precision in the 
circumstance of a rare outcome and adjustment for different durations of follow-up.
Study population
Patients were identified through the tumor registry or data warehouse of four sites: 
University of Chicago, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer 
Center (MSKCC), and the Siteman Cancer Center at Washington University (St. Louis). 
Institutional Review Board approval was obtained at each site. Eligible patients consisted of 
all women 21 years and older with incident invasive ductal carcinoma, Stages I-III, who 
were diagnosed between January 1, 2006 and December 31, 2011 and treated with 
mastectomy and immediate breast reconstruction. We excluded men, women younger than 
21, women with prior breast cancer, women with Stage IV or inflammatory breast cancer. 
We also excluded women who had delayed breast reconstruction to minimize heterogeneity 
in time intervals between diagnosis, treatment, and fat transfer. Only patients with invasive 
ductal carcinoma were included, so patients with DCIS only, lobular carcinoma in situ 
(LCIS) only, sarcoma, invasive lobular carcinoma, or no cancer were excluded.
Identification of cases and controls
Cases consisted of all eligible patients who had experienced a recurrence (local, regional, or 
distant) during the study period (January 1, 2006 to December 31, 2011) as reported by each 
site’s tumor registry or cancer data warehouse. The cohort was a 30% random sample of the 
control population, defined as patients who did not have a recurrence during the study 
period. Exposure to fat grafting was measured using medical record review in three sites and 
a prospectively maintained plastic surgery clinical database (at MSKCC). The approach of 
Cai and Zeng was used for power and sample size considerations.(24)
Statistical analyses
Fisher’s exact tests were used to evaluate general association for categorical data. The 
Wilcoxon rank-sum test (using Van der Waerden or normal scores) was used for two-group 
comparisons of continuous covariates. Cox proportional hazards regression modeling was 
used to explore the association of covariates of interest with time to recurrence. Time to 
recurrence was defined as the time from the date of diagnosis to the date of a local, regional, 
or distant cancer recurrence. Patients who reached the end of the study period, were lost to 
follow-up, or died, without documented disease recurrence were considered censored. The 
covariates of interest were: fat transfer (yes/no), age, tumor stage (I-III), smoking status 
(yes/no), body mass index (BMI), estrogen receptor (ER) status (+/−), progesterone receptor 
(PR) status (+/−), HER2/Neu amplification status (+/−), receipt of adjuvant chemotherapy 
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(yes/no), receipt of neo-adjuvant chemotherapy (yes/no), receipt of adjuvant radiation 
therapy (yes/no), and receipt of adjuvant endocrine therapy (yes/no).
We report both bivariate and multivariate estimated hazard ratios (HR) with 95% confidence 
intervals (CI). The final multivariate models did not include PR status because it was highly 
correlated with ER status. They did not include adjuvant therapies because they were highly 
correlated with stage. Statistical analyses were performed using SAS (Version 9.3, SAS 
Institute, Inc., Cary, NC) and R.(25)
RESULTS
We identified 3,271 eligible patients across the four institutions. The study sample (n=1197) 
consisted of all recurrences during the study period (n=225) and a 30% random sample of 
the study population (n=972) (Table 1). Based on this sample size, power was calculated to 
be 76% against a relative risk of 2 and 86% against a relative risk of 2.22, when using a one-
sided test with type-I error of 5%.
The median age was 47 (standard deviation (SD) 10.1). The median BMI was - 26.5 (SD 
5.6). Detailed in Table 1, almost half of the patients in the study sample had stage I disease, 
and most had ER+ and PR+ tumors. More than half received adjuvant chemotherapy while 
approximately one quarter received radiation, endocrine, or neo-adjuvant chemotherapy. 
While 80% of patients were reconstructed with breast implants, the remainder were 
reconstructed with autologous flaps, or a combination of flap and implant. Fat transfer was 
performed in 64 patients (5%), including 28 at MD Anderson, 26 at Memorial Sloan 
Kettering, 7 at Washington University, and 3 at the University of Chicago.
Two hundred and twenty-five patients or 6.9% of the entire study population, had a 
recurrence of breast cancer. Of these, 124 recurrences were distant (55%), 24 were regional 
(11%), and 77 were local (34%). Forty-eight (4%) patients died during the study period. In 
bivariate analyses of associations between individual covariates of interest and time to 
recurrence (Table 2), patients who underwent fat transfer had an equivalent risk of cancer 
recurrence, relative to those who did not (HR=0.99, 95% CI 0.56, 1.7). Patients with 
HER2/Neu+ tumors had a lower hazard of cancer recurrence than patients with HER2/Neu− 
tumors (HR=0.62, 95% CI 0.42, 0.91). Patients with ER+ tumors had 51% of the risk of 
patients with ER− tumors (p<0.0001). Stage II patients had a greater hazard of cancer 
recurrence than Stage I patients (HR=1.5, 95% CI 1.1, 2.1) and Stage III patients had a 
greater hazard of cancer recurrence than Stage II patients (HR=2.0, 95% CI 1.4, 2.8). In the 
multivariable model, adjusting for age, stage, BMI, HER2/Neu+ and ER+, patients who had 
fat transfer had similar risk of recurrence as those who did not have fat transfer (risk = 97%, 
p=0.93, see Table 3).
DISCUSSION
Fat transfer was not associated with an increased probability of breast cancer recurrence in 
this multi-center case-cohort study. While fat transfer to the breast has also been used in the 
context of reconstruction for partial mastectomy,(26) or as the sole technique of breast 
reconstruction following mastectomy,(27) we investigated fat transfer as an adjunctive 
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technique to prosthetic or flap-based reconstruction. Our findings are primarily applicable 
for patients with Stage I-III invasive ductal carcinomas treated with mastectomy and 
immediate breast reconstruction.
While several epidemiological studies report a link between obesity in post-menopausal 
women and breast cancer,(28–31) and translational research studies report that mesenchymal 
cells or ASCs support the progression of existing tumors,(10, 15, 16, 32–35) none show that 
adipocytes form tumors de novo.(5) As an endocrine organ, white adipose tissue may 
promote breast cancer through the secretion of adipokines like leptin,(36, 37) or insulin-like 
growth factor.(38) Further, reduced levels of adiponectin in obese patients fosters a 
permissive environment for the pro-oncogenic properties of leptin.(37, 39)
ASCs offer another mechanism by which white adipose tissue can simulate breast cancer 
cells. The progression of breast cancer is impacted by stromal cells of mesenchymal and 
hematopoetic origin.(5) Under defined conditions, adipocytes(40) and their progenitors 
promote tumorigenesis in both in vivo and in vitro models.(41) When ASCs are exposed to 
tumor-conditioned media secreted by breast cancer cell lines, they tend to proliferate, 
differentiate into myofibroblasts, enhance tissue stiffness through altered extracellular matrix 
deposition, secrete proangiogenic factors, and exhibit attenuated adipogenic differentiation.
(41) ASCs preferentially contribute vascular and fibrovascular tumor-associated fibroblasts 
to the tumor stroma while bone marrow-derived mesenchymal stem cells contribute 
fibroblast-specific proteins.(34) Co-culture of ASCs with breast cancer cells can also 
facilitate tumor metastases.(15, 42, 43) These important translational data speak to the 
potential consequences of using purified ASC grafts in the presence of active cancer cells. 
They may lead to the identification of molecular markers to predict cancer recurrence after 
fat grafting(42) but do not necessarily translate directly to current clinical practice. Unlike 
the immunocompromised nude mice receiving purified ASC cultures,(43) 
immunocompetent human patients typically receive fat grafts containing a variable, but low 
(2 to 8%) fraction of ASCs.(44, 45)
The absence of an association between fat transfer and recurrence risk reported here is 
consistent with experimental studies showing that white adipose tissue may stimulate active 
but not dormant breast cancers. Human ASCs significantly increase their malignant potential 
when co-cultured with active, but not dormant, breast cancer cells in vitro and in a 
xenogenic murine recipient in vivo model.(15) Under experimental conditions, invasive 
breast cancer cells alter the phenotype of adjacent mature adipocytes which, in turn, may 
increase the malignant potential of local breast cancer cells.(40)
Our findings are applicable to patients undergoing fat transfer following prosthetic or 
autologous reconstruction of mastectomy defects in the setting of stage I-III breast cancer. 
Following mastectomy, the engrafted recipient site contains little to no breast tissue. While 
some studies have suggested that adipocytes or their progenitors may stimulate active breast 
cancer,(10, 16) this could be less problematic if susceptible tissues have already been 
extirpated. By contrast, a significant percentage of residual breast tissue remains following 
partial mastectomy, another context in which fat transfer can be used for subsequent contour 
correction.(1) While an oncologically permissible environment for fat grafting may exist 
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when residual disease is resected and appropriate adjuvant therapy administered, increased 
recurrence risk may exist when fat is transferred in the presence of residual breast tissue.
(46–48) The European Institute of Oncology reported a locoregional recurrence rate of 0.4% 
per year following partial mastectomy among 2784 subjects.(49) However, a retrospective 
review of 143 partial mastectomy patients found that fat transfer was associated with a 
2.07% per year increased rate of locoregional recurrence.(7) By contrast, and in support of 
our data, recurrence rates in mastectomy patients after fat transfer increased 1.38% per year,
(7) versus 1.1% per year in a historical control group of 677 patients who did not receive fat 
transfer.(50) In the absence of a prospective trial, the authors of this multicenter 
retrospective review of 646 fat transfer patients recommended a cautious oncologic follow-
up protocol.(7)
Fat transfer may be associated with recurrence after DCIS, which we did not include in our 
study population. In a matched cohort study of 321 patients, a significantly higher incidence 
of local and locoregional recurrence after fat transfer was found when analysis was limited 
to patients with in situ disease.(6) A subsequent study limited to 59 patients with in situ 
disease who received fat transfer and a matched cohort of 118 who did not, revealed a higher 
rate of locoregional recurrence in the fat transfer group (HR=4.5, 95% CI 1.1, 18.2).(8) 
Patients younger than fifty, high grade neoplasia, and a Ki-67 ≥ 14, were also associated 
with an increased rate of recurrence after fat transfer in this study.
In Petit’s retrospective series, fat transfer was performed in 108 patients with in situ disease 
with a locoregional recurrence rate of 2.33% per year versus 1.44% per year in 405 patients 
with invasive carcinomas.(7) The molecular signature of the epithelial component of the 
tumor microenvironment that regulates extracellular matrix remodeling differs between 
DCIS and invasive ductal carcinoma.(51) Moreover, subtypes of DCIS can be differentiated 
by unique molecular signatures expressed by their fibroblasts, vascular, and inflammatory 
stromal cells.(52, 53) Recognizing these differences, Petit and colleagues(8) postulated that 
with fewer genetic perturbations than invasive carcinomas, intraepithelial neoplasias may be 
more efficient at responding to the stromal signaling that leads to malignant degeneration. 
Recently, this group re-analyzed their DCIS study population over a longer period of time, to 
increase the number of recurrence events evalauted.(26) Relative to controls, the recurrence 
rate was not higher in patients receiving fat transfer following mastectomy (p=0.56). It was 
somewhat higher in patients grafted following partial mastectomy, but the difference was not 
statistically significant (p=0.20). In addition, Gale and colleagues did not report an increased 
rate of recurrence following fat transfer in DCIS patients.(54) Fat transfer in these patients, 
however, was restricted to patients with clear margins and was delayed for 54 months after 
resection. By contrast, Petit waited a mean of 25 months and had positive or close margins 
in 42% of fat transferred patients but only 20% of controls, so the increased risk of 
recurrence may have been related to margin status.(8) Gale suggested that early fat transfer 
(≤2 years) after tumor resection may increase the impact of fat transfer on recurrence rates.
(54) Kronowitz et al. - who also support the oncologic safety of fat transfer in their study - 
suggest that lumpectomy accompanied by intraoperative radiation only, may have also 
impacted recurrence rates in Petit’s study.(22)
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Evaluation of the oncologic safety of fat transfer to facilitate breast reconstruction is 
challenging because recurrence of local or regional breast cancer after mastectomy is a 
relatively rare outcome,(55) many years of follow-up are necessary to evaluate recurrence,
(56, 57) and fat transfer has become common only recently. Thus, we used a retrospective 
case cohort approach. Our study was sufficiently powered to detect a risk ratio of 2 or 
greater, in terms of association between fat transfer and breast cancer recurrence. While a 
prospective, randomized controlled trial would be favorable over a retrospective analysis, it 
would be impractical to ask patients to agree to a control arm of no treatment for contour 
deformities. Finding an alternative control arm, such as temporary fillers or tissue 
rearrangement, would also be challenging. A prospective cohort study would also be useful 
but would require a substantially larger sample size and would not produce evidence for five 
to ten years. Finally, a study using existing large administrative or clinical datasets is not 
feasible because fat transfer does not yet have a unique billing code and is not routinely 
recorded in cancer registries. To address an urgent need for evidence on the safety of fat 
transfer to the breast,(58) we used a case-cohort study design, which is appropriate for 
assessing the probability of rare outcomes in a more timely fashion than a prospective cohort 
study.
The retrospective nature of this study is a limitation. In addition, we did not adjust for 
differences among fat transfer techniques due to a lack of consensus, nuanced technique 
differences not captured by retrospective review, and insufficient power to evaluate the 
impact of different fat transfer techniques on recurrence. Still, various methods of fat harvest 
and processing may affect adipocyte viability and stem cell fraction.(59–62) While 
optimization of the ASC-rich stromal vascular fraction of lipoaspirate may favor improved 
graft retention,(45) it may also increase the risk of exposure of ASCs to occult, residual 
tumor stroma.(45) All patients were treated at high-volume cancer centers and likely had 
access to timely cancer treatment and appropriate administration of adjuvant therapy.(48, 63) 
Thus, these results assume guideline-concordant care and may not be generalizable to all 
breast cancer patients. In addition, some of these patients may have sought a cancer center 
for their initial therapy but eluded detection of the institutional tumor registry for recurrences 
treated elsewhere. We only assessed patients having mastectomy and immediate 
reconstruction, a population that tends to be healthier, have greater economic resources, and 
have more favorable tumors than breast cancer patients overall.(64–66) Although we 
adjusted for some clinical variables, we did not adjust for health status or social factors. 
Future studies should include patients who have fat transfer after delayed reconstruction and 
after breast conservation therapy. As fat transfer to the breast becomes more common and 
acquires more indications, such studies ought to become more feasible.
CONCLUSION
Fat transfer was not associated with a higher probability of recurrence in this multi-site 
population of local and regional breast cancer patients treated with mastectomy and 
reconstruction. Although the precision of the study was somewhat limited, it provides 
evidence that fat transfer does not increase the probability of invasive breast cancer 
recurrence by a factor of at least 2.0. Future studies of a larger sample of immediate 
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reconstruction patients, and studies of fat transfer after delayed reconstruction or breast 
conservation therapy, are warranted.
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Table 1
Patient Characteristics
Patient Characteristics Total Cohort* Recurrence No Recurrence
 Age (SD) 47.78 (10.09) 44 48
 BMI (SD) 26.49 (5.62) 25 25
TNM Stage N (%)
 Stage I 585 (49) 77 (34) 508 (52)
 Stage II 448 (37) 92 (41) 356 (37)
 Stage III 164 (14) 56 (25) 108 (11)
Receptors
 HER2Neu+ 215 (20) 29 (13) 205 (22)
 ER+ 875 (74) 134 (60) 741 (78)
 PR+ 713 (61) 101 (46) 612 (64)
Treatment
 Adjuvant XRT + 319 (27) 110 (49) 209 (22)
 Adjuvant Chemotherapy + 689 (58) 153 (68) 536 (55)
 Adjuvant Endocrine + 1 (0) 25 (42) 252 (74)
 Neoadjuvant Chemotherapy + 250 (21) 82 (36) 168 (17)
Site
 MD Anderson 271 (23) 32 (14) 239 (25)
 Memorial Sloan Kettering 794 (66) 166 (74) 628 (65)
 University of Chicago 39 (3) 8 (4) 31 (3)
 Washington University, St. Louis 93 (8) 19 (8) 74 (8)
Totals 1197 (100) 225 (19) 972 (81)
Abbreviations: BMI Body Mass Index, TNM Tumor Nodal Metastasis, ER Estrogen Receptor, PR Progesterone Receptor
*
Values in parenthesis for Age and BMI represent standard deviation. All other values in parenthesis represent a percentage.













Myckatyn et al. Page 13
Table 2
Bivariate Time to Recurrence Models
Covariates Hazard Ratio 95% CI p-value
Age (for each 10 years) 0.81 (0.71, 0.93) 0.002
BMI (kg/m2) 0.98 (0.96, 1.01) 0.19
Stage II versus Stage I 1.5 (1.1, 2.1) 0.007
Stage III versus Stage II 2 (14, 2.8) <0.0001
HER2Neu+ versus HER2Neu− 0.62 (0.42, 0.91) 0.02
ER+ versus ER− 0.51 (0.39, 0.66) <0.0001
PR+ versus PR− 0.52 (0.40, 0.68) <0.0001
Fat Transfer (yes versus no) 0.99 (0.56, 1.7) 0.99
Abbreviations: BMI Body Mass Index, ER Estrogen Receptor, PR Progesterone Receptor
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Table 3
Multivariate Time to Recurrence Model
Covariates Hazard Ratio 95% CI p-value
Age (For each 10 years) 0.85 (0.75, 0.98) 0.02
BMI (kg/m2) 0.98 (0.96, 1.01) 0.11
Stage II versus Stage I 1.3 (0.95, 1.8) 0.13
Stage III versus Stage II 2.3 (1.6, 3.2) <0.0001
HER2Neu+ versus HER2Neu− 0.48 (0.32, 0.72) 0.0004
ER+ versus ER− 0.48 (0.37, 0.63) <0.0001
Fat Transfer (yes versus no) 0.97 (0.54, 1.8) 0.93
Abbreviations: BMI Body Mass Index, ER Estrogen Receptor, PR Progesterone Receptor
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